ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för ormaplatin. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

16 träffar

Bibliografisk träff 1999-01-01

Pharmacokinetics and biotransformations of oxaliplatin in comparison with ormaplatin following a single bolus intravenous injection in rats.

Luo FR, Wyrick SD, Chaney SG.

Cancer Chemother Pharmacol · comparative study; research support, u.s. gov't, p.h.s.; journal article · DOI 10.1007/s002800050940

Bibliografisk träff 1999-01-01

Comparative neurotoxicity of oxaliplatin, ormaplatin, and their biotransformation products utilizing a rat dorsal root ganglia in vitro explant culture model.

Luo FR, Wyrick SD, Chaney SG.

Cancer Chemother Pharmacol · comparative study; research support, u.s. gov't, p.h.s.; journal article · DOI 10.1007/s002800050941

Bibliografisk träff 1999-01-01

Phase I clinical and pharmacokinetic study of an one-hour infusion of ormaplatin (NSC 363812).

Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Feierabend C, Robins HI, Spriggs DR, Wilding G.

Invest New Drugs · clinical trial; research support, u.s. gov't, p.h.s.; clinical trial, phase i; journal article · DOI 10.1023/a:1006223100561

Bibliografisk träff 1998-12-01

Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model.

Holmes J, Stanko J, Varchenko M, Ding H, Madden VJ, Bagnell CR, Wyrick SD, Chaney SG.

Toxicol Sci · comparative study; research support, u.s. gov't, p.h.s.; journal article · DOI 10.1006/toxs.1998.2558

Bibliografisk träff 1998-07-01

Sensitivity to cisplatin and platinum-containing compounds of Schizosaccharomyces pombe rad mutants.

Perego P, Zunino F, Carenini N, Giuliani F, Spinelli S, Howell SB.

Mol Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1124/mol.54.1.213

Bibliografisk träff 1997-05-01

Pharmacokinetics of elemental platinum (ultrafiltrate and total) after a thirty minute intravenous infusion of ormaplatin.

Figg WD, Christian MC, Lush R, Link CJ, Davis P, Kohn E, Sarosy G, Rothenberg ML, Weiss RB, Ryan N, Jacobs J, Reed E.

Biopharm Drug Dispos · controlled clinical trial; clinical trial; clinical trial, phase i; research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.1002/(sici)1099-081x(199705)18:4<347::aid-bdd23>3.0.co;2-o

Bibliografisk träff 1996-08-01

Ormaplatin resistance is associated with decreased accumulation of its platinum (II) analogue, dichloro(D,L-trans)1,2-diaminocyclohexaneplatinum (II).

Rischin D, Ling V.

Br J Cancer · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/bjc.1996.406

Bibliografisk träff 1995-07-01

Effect of the chemoprotective agent WR-2721 on disposition and biotransformations of ormaplatin in the Fischer 344 rat bearing a fibrosarcoma.

Thompson DC, Wyrick SD, Holbrook DJ, Chaney SG.

Cancer Res · research support, u.s. gov't, p.h.s.; journal article

Bibliografisk träff 1995-01-01

Possible correlation between ormaplatin biotransformations and neurotoxicity.

Sakata M, Chaney SG, Spriggs DR.

Oncol Res · comparative study; research support, u.s. gov't, p.h.s.; research support, non-u.s. gov't; journal article

Bibliografisk träff 1995-01-01

Organ-specific biotransformation of ormaplatin in the Fischer 344 rat.

Thompson DC, Vaisman A, Sakata MK, Wyrick SD, Holbrook DJ, Chaney SG.

Cancer Chemother Pharmacol · research support, u.s. gov't, p.h.s.; journal article · DOI 10.1007/bf00686194

Bibliografisk träff 1994-10-01

Phase I clinical trial of ormaplatin (tetraplatin, NSC 363812).

O'Rourke TJ, Weiss GR, New P, Burris HA, Rodriguez G, Eckhardt J, Hardy J, Kuhn JG, Fields S, Clark GM.

Anticancer Drugs · clinical trial; research support, u.s. gov't, p.h.s.; clinical trial, phase i; journal article · DOI 10.1097/00001813-199410000-00002

Bibliografisk träff 1994-02-01

Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.

Schilder RJ, LaCreta FP, Perez RP, Johnson SW, Brennan JM, Rogatko A, Nash S, McAleer C, Hamilton TC, Roby D.

Cancer Res · clinical trial; clinical trial, phase i; journal article

Bibliografisk träff 1994-01-01

Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with a phase I clinical trial.

Petros WP, Chaney SG, Smith DC, Fangmeier J, Sakata M, Brown TD, Trump DL.

Cancer Chemother Pharmacol · clinical trial; research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1007/bf00685911

Bibliografisk träff 1993-10-01

Phase I and pharmacokinetic study of intraperitoneal ormaplatin.

Plaxe SC, Braly PS, Freddo JL, McClay E, Christen RD, Kirmani S, Kim S, Heath D, Howell SB.

Gynecol Oncol · clinical trial; research support, u.s. gov't, p.h.s.; research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1006/gyno.1993.1249

Bibliografisk träff 1993-01-01

Ormaplatin sensitivity/resistance in human ovarian cancer cells made resistant to cisplatin.

Parker RJ, Vionnet JA, Bostick-Bruton F, Reed E.

Cancer Res · journal article

Bibliografisk träff 1991-01-01

Solution chemistry and analytical characterization of ormaplatin.

Northcott SE, Marr JG, Secreast SL, Han F, Dezwaan J.

J Pharm Biomed Anal · journal article · DOI 10.1016/0731-7085(91)80038-b